| Dr Rusty A Moore, DO | |
|
544 S 400 E, 5th Floor, St George, UT 84770-3705 | |
| (435) 688-4700 | |
| (435) 688-4326 |
| Full Name | Dr Rusty A Moore |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 21 Years |
| Location | 544 S 400 E, St George, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205813474 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 76978781204 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Dixie Regional Medical Center | St george, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
Despite their widespread use by parents and caregivers, over-the-counter (OTC) cold and cough medicines have carried a warning by the FDA since 2008, and still have the potential to cause serious adverse events in infants and children. Conservative therapies, including nasal suctioning, humidification, and nasal saline, should be recommended over routine use of OTC cough/cold products in infants and children, according to a new commentary published in the May 2010 issue of Otolaryngology - Head and Neck Surgery.
Inflammatory bowel disease (IBD), which affects more than 1 million patients in North America, results from an uncontrolled immune response triggered by environmental factors, such as bacteria, in people genetically predisposed to the disorder. Ulcerative colitis, or inflammation of the lining of the colon, is one such condition.
Janssen Pharmaceuticals, Inc.announced today that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for the worldwide development, manufacturing and commercialization of VX-787, a novel medicine in Phase II development for the treatment of influenza A.
A clinical trial to test the safety, tolerability and efficacy of a combination treatment regimen for coronavirus disease 2019 (COVID-19) consisting of the antiviral remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, has begun.
› Verified 2 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629260880 PECOS PAC ID: 1850209420 Enrollment ID: O20031105000079 |
News Archive
Despite their widespread use by parents and caregivers, over-the-counter (OTC) cold and cough medicines have carried a warning by the FDA since 2008, and still have the potential to cause serious adverse events in infants and children. Conservative therapies, including nasal suctioning, humidification, and nasal saline, should be recommended over routine use of OTC cough/cold products in infants and children, according to a new commentary published in the May 2010 issue of Otolaryngology - Head and Neck Surgery.
Inflammatory bowel disease (IBD), which affects more than 1 million patients in North America, results from an uncontrolled immune response triggered by environmental factors, such as bacteria, in people genetically predisposed to the disorder. Ulcerative colitis, or inflammation of the lining of the colon, is one such condition.
Janssen Pharmaceuticals, Inc.announced today that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for the worldwide development, manufacturing and commercialization of VX-787, a novel medicine in Phase II development for the treatment of influenza A.
A clinical trial to test the safety, tolerability and efficacy of a combination treatment regimen for coronavirus disease 2019 (COVID-19) consisting of the antiviral remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, has begun.
› Verified 2 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942325154 PECOS PAC ID: 1850209420 Enrollment ID: O20080610000303 |
News Archive
Despite their widespread use by parents and caregivers, over-the-counter (OTC) cold and cough medicines have carried a warning by the FDA since 2008, and still have the potential to cause serious adverse events in infants and children. Conservative therapies, including nasal suctioning, humidification, and nasal saline, should be recommended over routine use of OTC cough/cold products in infants and children, according to a new commentary published in the May 2010 issue of Otolaryngology - Head and Neck Surgery.
Inflammatory bowel disease (IBD), which affects more than 1 million patients in North America, results from an uncontrolled immune response triggered by environmental factors, such as bacteria, in people genetically predisposed to the disorder. Ulcerative colitis, or inflammation of the lining of the colon, is one such condition.
Janssen Pharmaceuticals, Inc.announced today that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for the worldwide development, manufacturing and commercialization of VX-787, a novel medicine in Phase II development for the treatment of influenza A.
A clinical trial to test the safety, tolerability and efficacy of a combination treatment regimen for coronavirus disease 2019 (COVID-19) consisting of the antiviral remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, has begun.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Rusty A Moore, DO Po Box 27128, Salt Lake City, UT 84127-0128 Ph: () - | Dr Rusty A Moore, DO 544 S 400 E, 5th Floor, St George, UT 84770-3705 Ph: (435) 688-4700 |
News Archive
Despite their widespread use by parents and caregivers, over-the-counter (OTC) cold and cough medicines have carried a warning by the FDA since 2008, and still have the potential to cause serious adverse events in infants and children. Conservative therapies, including nasal suctioning, humidification, and nasal saline, should be recommended over routine use of OTC cough/cold products in infants and children, according to a new commentary published in the May 2010 issue of Otolaryngology - Head and Neck Surgery.
Inflammatory bowel disease (IBD), which affects more than 1 million patients in North America, results from an uncontrolled immune response triggered by environmental factors, such as bacteria, in people genetically predisposed to the disorder. Ulcerative colitis, or inflammation of the lining of the colon, is one such condition.
Janssen Pharmaceuticals, Inc.announced today that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for the worldwide development, manufacturing and commercialization of VX-787, a novel medicine in Phase II development for the treatment of influenza A.
A clinical trial to test the safety, tolerability and efficacy of a combination treatment regimen for coronavirus disease 2019 (COVID-19) consisting of the antiviral remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, has begun.
› Verified 2 days ago
Dr. Matthew Irvin, D.O. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 2825 E Mall Dr, St George, UT 84790 Phone: 801-354-8225 Fax: 435-627-1809 | |
Dr. Mette Hansen, MD Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 1490 E Foremaster Dr, St George, UT 84790 Phone: 435-628-9393 | |
Mr. Bryndon Blake Hatch, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 544 S 400 E, St George, UT 84770 Phone: 435-688-4700 | |
Diane Mary Vroenen, D.O. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 652 S Medical Center Dr, Ste 420, St George, UT 84790 Phone: 435-251-6800 | |
Dr. Bradley Dryden Root, D.O. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1424 E Foremaster Dr Ste 120, St George, UT 84790 Phone: 435-656-8800 Fax: 435-627-1809 | |
Dr. Max Robert Root, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1424 E Foremaster Dr, #120, St George, UT 84790 Phone: 435-656-8800 Fax: 435-627-1809 |